American CryoStem Corporation Engages Hanover Elite as Investor and Public Relations Counsel of Record
14 Março 2013 - 10:47AM
American CryoStem Corporation (OTCQB:CRYO), a
leading biotech company in the field of Regenerative Medicine,
today announced that it has named Hanover|Elite as the Company's
Investor and Public Relations counsel of record.
Hanover|Elite is a joint venture created through the partnership
of Hanover International, Inc. and Elite Financial Communications
Group. Hanover and Elite have teamed to leverage their respective
strengths, resources and spheres of influence on Wall Street
creating an innovative IR/PR model for applying best industry
practices in financial communications, corporate branding and
awareness, regulatory compliance and capital market access
services.
In collaboration with American CryoStem's senior leadership,
Hanover|Elite is charged with developing, implementing and
supporting a fully integrated corporate and shareholder
communications platform for the Company; generating meaningful
awareness among and measurable support from the retail and
institutional investment communities; and assisting management on
the formulation, refinement and execution of its short- and
long-term capital access strategies. Jim Hock, CEO of Hanover
and JV Managing Partner, along with Dodi Handy, CEO of Elite and JV
Managing Partner, will lead the combined IR/PR teams providing
strategic counsel and direction.
"American CryoStem appears to have reached a critical inflexion
point in its development and is well poised to distinguish itself
as a pioneering force in the emerging fields of Personalized and
Regenerative Medicine," stated Hock. "Consequently,
Hanover|Elite is very proud to be teaming with the Company to help
ensure that investors, investment professionals, industry
stakeholders and consumers, alike, come to know, appreciate and
support American CryoStem as it moves into what is anticipated to
be a highly dynamic phase of global growth and
differentiation."
About American CryoStem Corporation
American CryoStem Corporation is a leading biotech company
focused on marketing its clinical processing services and patented
products for adipose (fat) tissue and adipose derived adult stem
cells. Its clinical tissue processing, patented cell culture media
products and tissue storage platform supports cosmetic and
regenerative medicine applications currently being developed
globally. The Company provides high quality, clinically processed
viable cells, while at the same time is developing cutting edge
applications, therapies, patented laboratory products and services
for consumer and commercial applications. For more information,
visit www.americancryostem.com.
Cautionary Statement Regarding Forward Looking
Information
This Press Release contains "forward-looking" statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "may", "should", variations of such words and similar
expressions are intended to identify such forward-looking
statements. The forward-looking statements may include, without
limitation, statements regarding product development, product
potential or financial performance. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect the business of
American CryoStem Corp. and its markets, particularly those
discussed in the risk factors and cautionary statements in filings
made by the Company with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made, and the Company assumes any
responsibility to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
CONTACT: Hanover Elite
Jim Hock or Dodi Handy
407-585-1080 or via email at CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
American Cryostem (CE) (USOTC:CRYO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024